Back to News
Market Impact: 0.4
United Therapeutics Wins Patent Case Against Liquidia
Source: Nasdaq
Legal & LitigationPatents & Intellectual PropertyHealthcare & Biotech
United Therapeutics said a U.S. District Court in Delaware ruled that Liquidia Technologies infringed claims 1 and 14 of United Therapeutics' U.S. Patent No. 11,826,327, covering treatment of pulmonary disease. The ruling strengthens United Therapeutics' intellectual-property position and represents a legal setback for Liquidia, with potential implications for competing therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LQDA-0.85
UTHR0.80
More News
- United Therapeutics CEO Martine Rothblatt disposes of $3.9m in stock
- Cantor Fitzgerald reiterates United Therapeutics stock rating after patent win
- Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more
- Can Trump Oust Powell From the Fed Board? What to Know
- Nvidia Faces Questions Over China AI Chip Smuggling Cases
- New Mexico wants Meta to pay up to $40 billion in penalties after data privacy trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI for Sell-Side Models, Estimates, and Internal Data
- How to Write an Investment Memo with AI: A Decision-Record Template